The three-dimensional structure of the ternary complex consisting of human -thrombin, hirugen and the active-site inhibitor RWJ-51438 has been determined at 1.7 A Ê resolution. The crystals of the complex belong to the orthorhombic space group P2 1 2 1 2, with unit-cell parameters a = 62.98, b = 117.52, c = 47.99 A Ê . The re®ned R and R free values are 0.196 and 0.232, respectively. The ketone carbonyl group of the inhibitor is covalently linked to the hydroxyl O atom of Ser195, forming a tetrahedral intermediate hemiketal structure; the benzothiazole ring N atom of RWJ-51438 forms a hydrogen bond with His57. Surprisingly, the carboxylate substituent on the benzothiazole group forms salt bridges with Lys60F NZ and the NZ of the symmetry-related residues Lys236 and Lys240, which introduces steric effects that perturb the 60A±60I insertion loop, especially at residues Trp60D and Phe60H.
The three-dimensional structure of the ternary complex consisting of human -thrombin, hirugen and the active-site inhibitor RWJ-51438 has been determined at 1.7 A Ê resolution. The crystals of the complex belong to the orthorhombic space group P2 1 2 1 2, with unit-cell parameters a = 62.98, b = 117.52, c = 47.99 A Ê . The re®ned R and R free values are 0.196 and 0.232, respectively. The ketone carbonyl group of the inhibitor is covalently linked to the hydroxyl O atom of Ser195, forming a tetrahedral intermediate hemiketal structure; the benzothiazole ring N atom of RWJ-51438 forms a hydrogen bond with His57. Surprisingly, the carboxylate substituent on the benzothiazole group forms salt bridges with Lys60F NZ and the NZ of the symmetry-related residues Lys236 and Lys240, which introduces steric effects that perturb the 60A±60I insertion loop, especially at residues Trp60D and Phe60H.
Introduction
Thrombin is a serine protease that plays a central role in homeostasis and thrombosis (Blomback et al., 1967; Mann, 1976; Berliner, 1992) . One of the many important functions of thrombin is to catalyze the cleavage of ®brinogen to produce ®brin, which is a polymeric meshwork that stabilizes a blood clot resulting in a durable homeostatic plug (Davie et al., 1991) . Thrombosis can be regarded as a result of inappropriate thrombin activity. Consequently, thrombin is a potential therapeutic target for the treatment and prevention of thrombotic diseases.
-Thrombin contains at least three areas of interaction with substrates and inhibitors ( Fig. 1) : (i) an active site comprising the catalytic triad (Ser195, His57 and Asp102) and the P1 speci®city pocket that binds arginyl and lysyl side chains of substrate, (ii) a cationic ®brinogen-recognition exosite formed by residues Phe34±Leu40 and Arg73±Met84 at the bottom of a cliff-like wall that usually operates in concert with catalysis and (iii) an anion-binding exosite that is involved in heparin binding. This last site, which consists of the cationic residues Lys240, Lys233, Arg175, Arg101 and Arg93, also binds the second kringle domain of prothrombin through salt bridges.
A large number of inhibitor±thrombin complexes have been studied by X-ray crystallography , helping us to understand the roles that thrombin plays; however, little is known about the binding at the S H sites. We are studying novel tripeptide transition-state analogues of the general form d-Phe-Pro-Arg-X, where X is a heterocyclic activating group. Two examples of such compounds are benzothiazoles I and II (Table 1) . The use of a heterocycle at the P1 H position imparts the necessary electrophilicity to the arginine carbonyl moiety of the inhibitor (Edwards et al., 1992; Acta Cryst. (2000) . D56, 1395±1400 Tsutsumi et al., 1994; Costanzo et al., 1996; Matthews et al., 1996; Recacha et al., 1999) . An advantage of such heterocycleactivated ligands over those with other electrophilic ketones is the availability of heterocycles that can be incorporated into a peptidyl ketone, allowing modulation of the physiochemical properties.
We have determined the crystal structure of a complex of human -thrombin with hirugen and the benzothiazolecontaining inhibitor RWJ-51438 (II) at 1.7 A Ê resolution. The inhibitor, (S)-N-methyl-d-phenylalanyl-N-{4-[(aminoiminomethyl)amino]-1-[(6-carboxy-2-benzothiazolyl)carbonyl]butyl}l-prolinamide tri¯uoroacetate hydrate (II), is a highly selective and potent inhibitor of thrombin (K i = 1.1 AE 0.6 nM). The structural differences between RWJ-50353±thrombin (Matthews et al., 1996) , which lacks a CO 2 H substituent on the benzothiazole, and RWJ-51438±thrombin may explain the loss in thrombin af®nity of RWJ-51438 (II) relative to RWJ-50353 (I) (K i = 0.14 AE 0.03 nM), despite the additional interactions in RWJ-51438±thrombin.
Here, we present the most important features of the human -thrombin structure, its interactions with RWJ-51438 derived from the fully re®ned structure and its comparison with other thrombin complex structures.
Materials and methods

Crystallization
Frozen samples of human -thrombin at a concentration of 1.12 mg ml À1 in 0.75 M sodium chloride solution were supplied by John W. Fenton (Fenton et al., 1977) . An approximately tenfold molar excess of hirugen, in the solid state, was added to a frozen 1 ml sample of thrombin and allowed to form complex for 2 h on ice and prevent the autolysis. The solution of the hirugen±thrombin complex was diluted to 2 ml with 50 mM phosphate buffer pH 7.3 and concentrated to about 6 mg ml À1 using a Centricon 10 miniconcentrator (MW cutoff 10 kDa) in a refrigerated centrifuge.
Concentrated thrombin±hirugen complex was incubated with a tenfold molar excess of RWJ-51438 for 2 h at 277 K. Crystallization was carried out at room temperature using the hanging-drop technique. Drops of 3 ml ternary complex solution mixed with 3 ml reservoir solution were equilibrated against 1 ml of well solution containing 0.1 M sodium cacodylate buffer pH 6.5, 0.75 M sodium acetate, 0.01%(w/v) sodium azide and 20%(w/v) polyethylene glycol 4000. Crystals suitable for X-ray diffraction, approximately 0.3 Â 0.05 Â 0.05 mm in size, were obtained after 5 d.
Data collection
X-ray diffraction data were collected at 103 K, using 25% glycerol in the reservoir solution as cryoprotectant, on an R-AXIS IV image plate and were processed with DENZO (Otwinowski & Minor, 1997). The completeness of data at 1.66 A Ê resolution is of 87.1%. The R merge is 4% and the overall I/' is 16.3. Table 1 Benzothiazole-activated thrombin inhibitors RWJ-50353 and RWJ-51438.
Compound
Structure
RWJ-50353 I 0.14 AE 0.03 (n = 30) 2.3 AE 1.1 (n = 6) RWJ-51438 II 1.1 AE 0.6 (n = 8) 3.1 AE 0.07 (n = 9)
Figure 1
Ribbon drawing of the ternary complex thrombin±hirugen±RWJ-51438. The thrombin L-chain and hirugen ribbons are green and light blue, respectively. The thrombin H-chain is lavender with the insertion loop magenta. The cationic ®brinogen-binding loops on the right side (residues 34±40 and 73±84) and the heparin-binding residues (see text) on the left side are blue and the autolytic loop (residues 146±150) is gold. Side chains of the catalytic triad residues His57, Asp102 and Ser195 are blue, red and orange, respectively. The inhibitor is colored by atom type. All ®gures were prepared with Ribbons (Carson, 1997; http://www.cmc.uab.edu/ ribbons) unless otherwise noted.
Structure determination and refinement
A search for the orientation and position of the thrombin molecule in the orthorhombic cell was performed using the program AMoRe (Navaza, 1994), diffraction data in the range 20±3.5 A Ê and the coordinates of a non-isomorphous thrombin±hirugen complex model (PDB code 1tmu; Priestle et al., 1993) . Fourier maps calculated after appropriate positioning of the thrombin molecule in the crystal cell allowed the rebuilding of the autolysis loop and addition of the omitted parts of the thrombin L-chain using the program QUANTA. The model of the thrombin±hirugen complex with uniform isotropic thermal (15.0 A Ê 2 ) and occupancy parameters was used for the initial re®nement using X-PLOR (Bru È nger et al., 1987) . The RWJ-51438 inhibitor was located after the ®rst round of re®nement. Simulated annealing with slow cooling (Bru È nger et al., 1990) and conjugate-gradient minimization were carried out. The re®nement data were gradually extended to 1.7 A Ê resolution during the re®nement. Solvent molecules were inserted at reasonable positions where the difference electron density exceeded 2.5'. Finally, the individual atomic isotropic B factors were re®ned. Crystallographic statistics for the structure are reported in Table 2 .
To provide a rigorous test for the accuracy of the model, omit maps covering a portion of the structure were computed following a simulated-annealing procedure in which coordinates of the portion of the model to be tested were removed (X-PLOR, v. 3.85). For the complex structure including 354 water molecules and two sodium ions, the R and R free values are 19.6 and 23.2%, respectively, for 35 906 re¯ections (resolution limits 8±1.7 A Ê ). The mean B-factor value for all atoms is 19.5 A Ê 2 . The ®nal atomic coordinates and structure factors have been deposited with the Protein Data Bank (RCSB number 010249; PDB code 1doj).
Results and discussion
Crystals of the RWJ-51438±hirugen±thrombin ternary complex belong to the orthorhombic space group P2 1 2 1 2, with unit-cell parameters a = 62.98, b = 117.52, c = 47.99 A Ê . All the residues lie within the allowed regions of the Ramachandran plot with the exception of residue Phe7, which is in the generously allowed area.
Thrombin structure
The numbering of the thrombin residues used is based on topological equivalences with chymotrypsin (Hartley & Shotton, 1971 ). In this system, L-chain residues are numbered 1H±15 and H-chain residues are numbered 16±247, with insertions relative to the chymotrypsinogen structure numbered alphanumerically. The N-terminal residues of the L-chain of thrombin that precedes residue 1 in chymotrypsinogen are numbered in reversed alphanumerical order. The residues of hirugen are numbered 53 H ±64 H , with 53 H designating the N-terminal Ac-Asn residue and 64 H designating the C-terminal Leu.
Electron density was well de®ned for most of the structure. The amino-terminal segment of the L-chain within the autolysis loop (Glu1C±Thr1H) and the C-terminus of the H-chain are only de®ned by relatively weak densities in the present structure and the amino-acid residues in these areas have been re®ned with occupancy lower than unity. These regions are typically found to be disordered in other thrombin complexes (Skrzypczk-Jankun et al., 1991; Vijayalakshmi et al., 1994) . The weakly de®ned amino-terminal segment preceding Cys1 leans against a hydrophobic depression formed by Phe114 and Ile47 and extends with its amino-terminal residue 1H towards the carboxy-terminus of the L-chain. As is described in some Table 2 Crystallographic data for human -thrombin±RWJ-51483. 
Figure 2
Surface of the active site colored by atomic chemical property. Positively charged atoms are blue, hydrogen-bond donors are cyan, negatively charged atoms are red, hydrogen-bond acceptors are orange, polar atoms (donators or acceptors) are magenta and hydrophobic atoms are white. The inhibitor is colored by atom type. Key surface residues are labelled.
structures , the carboxyl-terminal segment Glu14C±Ser14I is organized as an amphiphilic -helix, with its hydrophobic side (Val14B, Leu14E, Leu14G, Tyr14J) attached to the H-chain (Fig. 1) . The lytic loop containing Trp148 is generally well de®ned, being stabilized by the crystallographic contacts. As in the structure of thrombin with PPACK (d-Phe-Pro-Arg chloromethylketone; Bode et al., 1992 ), the exposed loop lacks any inter-main-chain hydrogen bonds, but it is stabilized through hydrogen bonds made with the side chains of residues within the loop. In addition, some contacts with a symmetry-related molecule stabilize this loop in the present complex structure, as was observed in the PPACK±thrombin structure. The conformation of this loop in the present structure is different from that in the PPACK±thrombin complex. This loop exhibits a degree of¯exibility (average B factor = 29 A Ê 2 ) in this structure. The present thrombin structure is similar to that of RWJ-50353±thrombin complex (r.m.s.d. C = 0.46 A Ê ; PDB code 1tbz). The latter structure will be used throughout the text for comparison purposes.
The two N-terminal residues of hirugen (N-acetyl-Asn-Gly) are not observed in the electron-density map. The rest of the hirugen molecule from residue Asp55 H to Gln64 H is well de®ned. The interactions are comparable to those in the binary hirugen±thrombin complex .
Active-site interactions
The active-site triad (Ser195, His57 and Asp102) shown in Fig. 1 is similar to that of the binary hirugen±thrombin complex structure (Vijayalakshmi et al., 1994) . The binding of the inhibitors in the active site does not signi®cantly affect the overall structure of thrombin (Stubbs & Bode, 1993; De Simone et al., 1998) . Its groove extension is in fact created by a patch of positively charged side chains (Fig. 2) , Lys36, Lys60F, Arg67, Arg75 and Arg77A. The last residue presents two distinct orientations in this structure.
The inhibitor RWJ-51438 is well de®ned in the electrondensity map (Fig. 3) . The binding of RWJ-51438 is similar to that of RWJ-50353; both belong to the PPACK class of inhibitors. The overall interactions between RWJ-51438 at the P1, P2 and P3 positions and thrombin are similar to complexes of thrombin with RWJ-50353 and PPACK (Matthews et al., 1996) . To describe the interactions between thrombin and the inhibitor, the nomenclature introduced by Schechter & Berger (1967) is used. The position of the reactive site of the inhibitor is known as the primary binding site or P1 position. The Ser195 OG atom of thrombin forms a hemiketal intermediate with the carbonyl C atom of the P1 arginine of RWJ-51438, with a bond length of 1.4 A Ê . The geometry of the substituents around the carbonyl C atom is tetrahedral (Fig. 3) , with the carbonyl O atom occupying the oxyanion hole, making hydrogen bonds with Gly193 N and Ser195 N ( Table 3) . The N-Me-d-Phe-Pro-Arg motif has all the interactions previously observed in inhibitor±thrombin complexes with this sequence binding in the active site ( Fig. 4 ; Table 3 ). There is a doubly hydrogenbonded ion pair of the P1 arginine guanidinium group with Asp189 in the S1 speci®city pocket. In addition, one of the (Bode et al., 1989 .
P1 H H H interactions
The structures of thrombin complexes with thiazole inhibitors similar to RWJ-51438 have been reported. The comparison of RWJ-50353±thrombin (Matthews et al., 1996; Costanzo et al., 1996) and MOL-168± thrombin (Charles et al., 1999) with the complex structure studied here shows similarities in the binding of the inhibitor to the protein. However, differences in binding of RWJ-51438 to thrombin are apparent owing to the presence of the carboxylate substituent on the benzothiazole (Bzt) ring. The active site of thrombin is particularly narrow when compared with other serine proteases of the same family. Hence, the presence of the carboxylate group in RWJ-51438 affects some residues of the 60A±60I insertion loop (Fig. 5) , which is compact and somewhat rigid . A similar orientation was observed for the benzothiazole ring of the inhibitors RWJ-50353 (Matthews et al., 1996) and MOL-168 (Charles et al., 1999) complexed with thrombin. The thiazole S atom of the inhibitor points toward Glu192 and interacts with the amide N atom of Gly193 (3.5 A Ê ). Residue Glu192, which is found in ā exible orientation in several thrombin±inhibitor complexes, is ordered in the present structure and interacts with the arginine residue of the inhibitor through a watermediated hydrogen bond [NEÐ O(W589)ÐGlu192 OE1; Fig. 4 , Table  3 ]. This residue seems to be crucial for stabilizing the inhibitor or the substrate in the active site . There is a hydrogen bond between His57 and the benzothiazole ring N atom which could delocalize the positive charge of a protonated N atom through the heterocyclic ring to the hemiketal O atom, resulting in further stabilization of the transitionstate oxyanion (Edwards et al., 1992) .
The interactions of Lys60F appear to play an important role in the biological activity of thrombin (Wu et al., 1991) . The terminal side-chain Stereoview of the thrombin±RWJ-51438 complex compared with the thrombin±RWJ-50353 complex. The RWJ-50353 complex is shown in the same manner, except the ribbon and all the C atoms are green.
Figure 4
Diagram representing the key interactions between RWJ-51438 and thrombin. atoms of Lys60F in the structure of the RWJ-50353±thrombin complex curl away relative to the hirugen±thrombin complex in order to accommodate the bulky benzothiazole ring in the S1 H subsite (r.m.s.d. side chain = 1.564 A Ê ). However, the carboxyl group joined to the benzothiazole ring forms a hydrogen bond with Lys60F NZ in the present structure. As a result, the displacement of the Lys60F side chain is not so pronounced. The amino group of the Lys60F does not form a hydrogen bond with the carbonyl O atom of His57. Usually, this particular hydrogen bond is formed when the S1 H subsite is either unoccupied or occupied by a small residue such as glycine . The carboxylate group joined to the benzothiazole ring also forms a hydrogen bond with a water molecule (see Table 3 ) and forms a salt bridge with the NZ atoms of the symmetry-related residues Lys236 and Lys240.
Residues that form the groove joining the two functional sites of thrombin, especially the residues of the 60A±60I insertion loop, Trp60D and Phe60H, take different positions in the two complexes because of the presence of the carboxylate group in RWJ-51438 ( Fig. 5 ). Whereas the non-bonded distance between the benzothiazole and the Trp60D in the present structure is shorter in comparison with the complex RWJ-50353±thrombin structure, leading to stronger van der Waals interactions, the remaining residues are more distant (Fig. 5) . The S1 H subsite of thrombin generally accommodates smaller side chains as observed from the P1 H residues of a number of natural substrates (Qiu et al., 1992) . These residues include glycine and threonine and, in some cases, apolar residues such as Val15 of ®brinogen A, Leu13 of protein C and Ile153 and Ile37 of factor VII and factor XI, respectively (Tulinsky & Qiu, 1993; . The S1 H site is therefore capable of harboring moderately bulky side groups, although it appears to prefer smaller ones (Qiu et al., 1992) . The steric effects exerted by the carboxylate group may explain the higher K i value of RWJ-51438 for thrombin than that of RWJ-50353. The perturbation of the insertion loop arises from a combination of effects of the negatively charged carboxylate ion that favor the approach of positively charged residues in its vicinity. This includes movement of the Lys60F toward the carboxylate end of the inhibitor. This work was supported by funds from the R. W. Johnson Pharmaceutical Research Institute.
